Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo
about
Demonstration of viral thymidine kinase inhibitor and its effect on deoxynucleotide metabolism in cells infected with herpes simplex virusDrug combinations for treatment of mice infected with acyclovir-resistant herpes simplex virusA new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxyl]methyl]guanine, highly active in vitro against herpes simplex virus types 1 and 2Enzymology and pathogenicity in mice of a herpes simplex virus type 1 mutant resistant to 2'-fluoro-2'-deoxy-1-beta-D-arabinofuranosyl-5-iodocytosineSusceptibility to other antiherpes drugs of pathogenic variants of herpes simplex virus selected for resistance to acyclovirRapid phenotypic characterization method for herpes simplex virus and Varicella-Zoster virus thymidine kinases to screen for acyclovir-resistant viral infection.Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and managementChemotherapy for herpes simplex virus infectionsMurine gammaherpesvirus 68 lacking thymidine kinase shows severe attenuation of lytic cycle replication in vivo but still establishes latencyHerpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapyGenetic metamorphosis of herpes simplex virus-1 into a biological therapeutic for human cancer.Orofacial infection of athymic mice with defined mixtures of acyclovir-susceptible and acyclovir-resistant herpes simplex virus type 1Acyclovir prophylaxis for herpes simplex virus infection.Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.Oral acyclovir therapy of genital herpes simplex virus type 2 infections in guinea pigs.Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovirThe range and distribution of murine central nervous system cells infected with the gamma(1)34.5- mutant of herpes simplex virus 1.Antiviral therapy: current concepts and practicesH-2-linked genes influence the severity of herpes simplex virus infection of the peripheral nervous system.Pathogenesis of experimental skin infections induced by drug-resistant herpes simplex virus mutants.Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant.Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene.Differential effects of acyclovir and 9-(1,3-dihydroxy-2-propoxymethyl)guanine on herpes simplex virus and Epstein-Barr virus in a dually infected human lymphoblastoid cell line.Trigeminal ganglion infection by thymidine kinase-negative mutants of herpes simplex virus after in vivo complementation.Establishment of latency in mice by herpes simplex virus 1 recombinants that carry insertions affecting regulation of the thymidine kinase gene.Alterations in substrate specificity and physicochemical properties of deoxythymidine kinase of a drug-resistant herpes simplex virus type 1 mutant.Mutations in the herpes simplex virus DNA polymerase gene can confer resistance to 9-beta-D-arabinofuranosyladenine.Herpes simplex virus 1 targets the murine olfactory neuroepithelium for host entryDifferentiation of herpes simplex virus types 1 and 2 by sensitivity to (E)-5-(2-bromovinyl)-2'-deoxyuridine.Association between sensitivity of viral thymidine kinase-associated acyclovir-resistant herpes simplex virus type 1 and virulence.Herpesvirus and enteric viral infections in bone marrow transplantation: clinical presentations, pathogenesis, and therapeutic strategies.Persistent herpes simplex virus infection and mechanisms of virus drug resistance.Herpes simplex virus latency: adaptation to the peripheral nervous system. II.Biological and biochemical characterization of clinical isolates of herpes simplex virus type 2 resistant to acyclovir.Plaque autoradiography assay for the detection and quantitation of thymidine kinase-deficient and thymidine kinase-altered mutants of herpes simplex virus in clinical isolates.Development of clinical resistance to acyclovir in herpes simplex virus-infected mice receiving oral therapy.Advances in antiviral therapy: acyclovir.In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus.Antiherpes drugs: promises and pitfalls.Properties of a novel thymidine kinase induced by an acyclovir-resistant herpes simplex virus type 1 mutant.
P2860
Q28360575-6873CE08-1835-47B1-8279-42D182B80099Q28361799-C5752869-E6B6-4C47-B4C0-90F382E18DFDQ28366181-06B25FEB-1655-4616-BA8A-D6D467064C4DQ33739362-B3BEB420-8722-413E-A6C5-E8159DE0F19BQ33739521-D4DDE68E-9335-439C-AA85-1BA66E3F03B4Q33966906-7288A539-31F0-4E6D-A3CD-509557AD4281Q34149904-A0BC03FD-F444-4A0B-882D-4479E8683C8EQ34193041-09D32869-25EE-42C3-8800-0468AEAC5894Q34471133-C39DF7EC-6F85-403A-A80D-7CE189B289F5Q34579981-725FF90B-7612-4BD2-9ADD-12154FCE639EQ35116166-1DE536EF-5B3B-44AA-B519-30A3CAE08048Q35244752-F3AD058E-7BC4-4981-B154-695CF2220471Q35537506-570771A3-64C2-498B-821D-18A3DA12ACC5Q35540860-BCA34926-1C7C-424D-B715-87393DBF5C6AQ35569432-72E869A6-3491-406F-823F-467B9F400006Q35647877-6AFCE3F0-21E2-45A5-BB79-6F34BEA4F5A4Q35888685-06138B8B-9FD9-404D-85C6-EAA12E4BBB43Q36070394-DEF642F8-6697-4A5E-8CD1-3AEEEE3EF19CQ36356050-E52A80BC-2AFC-4325-8EC0-091E70033713Q36431381-C803331E-2366-4175-B892-8C0BD9C038FBQ36826076-8A4D84DD-D48D-4A07-AD34-069F42468209Q36883978-3F243783-7470-49C4-826A-7F2CFE44EDAEQ36884995-8ECB9ECB-6100-4F07-A695-161D064047CBQ36889822-2A110464-9802-4CE7-B417-4B0BB8819A7DQ36903318-83543D67-2D3E-4686-A858-694B51E24BF5Q36932482-2866BC09-07FB-4585-9C3D-D3DA790BEBFBQ36939346-9093506D-9464-4BB4-901D-E380C9AF1E02Q37252909-2727FE9F-4BD2-487D-8966-70441BDA71A6Q37291578-3997D9BA-059D-4F4E-8942-520DBBEBCCFFQ37713430-EE813D10-2722-4225-8684-F9517F44A1C0Q37901418-36F3FAF8-371E-43E2-90E1-22800B64807CQ38287183-8DEC13F1-AACC-447C-BC4E-A641A6A59C1BQ39495819-1EE20B0C-9856-4C76-8274-95597AF10049Q39819155-F4A38164-5393-4D66-88BD-D0B7151E3671Q39850127-5266C5E6-31C1-40DD-B98D-762D0948CCA4Q39857055-ED7BE63E-7D12-4280-8178-A25BAFAEB29BQ40079186-07A9E215-F277-4CD2-B014-2C83F19846BBQ40088021-F066CF4A-33A2-498E-9737-7479B4B01A5BQ40142222-EACD4C79-B904-439C-B37D-D2C5FC36E25CQ40145611-1175516C-C5E0-4D41-B6CA-2135CE9DA06B
P2860
Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo
description
1980 nî lūn-bûn
@nan
1980 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1980 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1980年の論文
@ja
1980年論文
@yue
1980年論文
@zh-hant
1980年論文
@zh-hk
1980年論文
@zh-mo
1980年論文
@zh-tw
1980年论文
@wuu
name
Pathogenicity in mice of strai ...... acyclovir in vitro and in vivo
@ast
Pathogenicity in mice of strai ...... acyclovir in vitro and in vivo
@en
Pathogenicity in mice of strai ...... acyclovir in vitro and in vivo
@nl
type
label
Pathogenicity in mice of strai ...... acyclovir in vitro and in vivo
@ast
Pathogenicity in mice of strai ...... acyclovir in vitro and in vivo
@en
Pathogenicity in mice of strai ...... acyclovir in vitro and in vivo
@nl
prefLabel
Pathogenicity in mice of strai ...... acyclovir in vitro and in vivo
@ast
Pathogenicity in mice of strai ...... acyclovir in vitro and in vivo
@en
Pathogenicity in mice of strai ...... acyclovir in vitro and in vivo
@nl
P2860
P356
P1476
Pathogenicity in mice of strai ...... acyclovir in vitro and in vivo
@en
P2093
P2860
P304
P356
10.1128/AAC.17.2.209
P407
P577
1980-02-01T00:00:00Z